 |
 |
|
Home |
Current Issue |
Past Issues |
In the Clinic |
ACP Journal Club |
CME |
Collections |
Audio/Video |
Mobile |
Subscribe |
Tools |
Help |
ACP Online
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Summaries for Patients are a service provided by Annals to help patients better understand the complicated and often mystifying language of modern medicine.
SUMMARIES FOR PATIENTS
Postmenopausal Hormone Replacement Therapy To Prevent Chronic Conditions: Recommendations from the U.S. Preventive Services Task Force
20 August 2002 | Volume 137 Issue 4 | Page I-48
Summaries for Patients are presented for informational purposes only. These summaries are not a substitute for advice from your own medical provider. If you have questions about this material, or need medical advice about your own health or situation, please contact your physician. The summaries may be reproduced for not-for-profit educational purposes only. Any other uses must be approved by the American College of Physicians-American Society of Internal Medicine.
The summary below is from the full reports titled "Postmenopausal Hormone Replacement Therapy for Primary Prevention of Chronic Conditions: Recommendations and Rationale" and "Postmenopausal Hormone Replacement Therapy and the Primary Prevention of Cardiovascular Disease." The first report is in the 19 November 2002 issue of Annals of Internal Medicine (volume 137, pages 834-839), and the second report is in the 20 August 2002 issue (volume 137, pages 273-284). The first report was written by the U.S. Preventive Services Task Force; the second report was written by LL Humphrey, BKS Chan, and HC Sox. The complete USPSTF recommendation and rationale statement and the complete information on which this statement is based are available at http://www.preventiveservices.ahrq.gov.
What is the U.S. Preventive Services Task Force?
The U.S. Preventive Services Task Force (USPSTF) is a group of health experts that reviews published research and makes recommendations about preventive health care.
What is the problem and what is known about it so far?
Around menopause, decreases in the levels of the hormones estrogen and progesterone result in hot flashes, night sweats, mood swings, and vaginal dryness. Lower hormone levels also increase bone loss and the risk for heart disease. Postmenopausal hormone replacement therapy (HRT) consists of taking estrogen with or without progesterone. Some women take HRT to relieve the uncomfortable symptoms of menopause. Others take it to reduce the risk for osteoporosis (thinning of the bones that can lead to fractures), which is a proven effect of HRT, and some take HRT with the hope of decreasing their chances of heart disease, colon cancer, or dementia. However, the effect of HRT on these conditions has been uncertain. HRT has side effects and does appear to increase the risk for certain diseases such as stroke, blood clots, and breast cancer. It has been unclear whether the potential benefits of postmenopausal HRT to prevent some chronic conditions are worth the associated risks.
How did the USPSTF develop these recommendations?
The USPSTF reviewed published research to evaluate the benefits and harms of postmenopausal HRT.
What did the authors find?
The most certain long-term benefit of HRT is the decreased risk for osteoporosis-related fractures. Possible but unproven benefits include reduced risk for dementia. HRT using only estrogen also increases the risk for uterine cancer, but a woman can eliminate this risk by taking progesterone with estrogen. Other negative effects of HRT include blood clots and gallstones. A recent study, the Women's Health Initiative, provided strong evidence that HRT causes small but definite increases in a women's risk for heart disease, stroke, and breast cancer. This study showed that HRT decreases the risk for colon cancer and for osteroporosis-related fractures. Since HRT increases the risk for heart disease and breast cancer, the harms outweigh the benefits for most women.
What does the USPSTF suggest that patients do?
The USPSTF recommends against women taking HRT for the sole purpose of preventing chronic conditions. The decision about whether to take HRT to reduce the symptoms of menopause will depend on each woman's preferences and personal risk for osteoporosis, heart disease, dementia, blood clots, stroke, and cancer. Women considering taking HRT for any reason should discuss the potential benefits and risks with their doctors.
What are the cautions related to these recommendations?
As better studies become available, the USPSTF may modify these recommendations. These recommendations do not address decisions about whether to use short-term HRT (<5 years) to treat menopausal symptoms or the use of estrogen alone after hysterectomy.
Related articles in Annals:
This article has been cited by other articles:
|
|
 |
|
  M. L. Power, J. Baron, and J. Schulkin Factors Associated with Obstetrician-Gynecologists' Response to the Women's Health Initiative Trial of Combined Hormone Therapy Med Decis Making, June 1, 2008; 28(3): 411 - 418. [Abstract] [PDF]
|
|
|
|
 |
|
 E. P. Whitlock, J. S. Lin, R. Chou, P. Shekelle, and K. A. Robinson Using Existing Systematic Reviews in Complex Systematic Reviews Ann Intern Med, May 20, 2008; 148(10): 776 - 782. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. H Guyatt, A. D Oxman, G. E Vist, R. Kunz, Y. Falck-Ytter, P. Alonso-Coello, H. J Schunemann, and for the GRADE Working Group GRADE: an emerging consensus on rating quality of evidence and strength of recommendations BMJ, April 26, 2008; 336(7650): 924 - 926. [Full Text] [PDF]
|
|
|
|
 |
|
 N. B. Ojeda, D. Grigore, E. B. Robertson, and B. T. Alexander Estrogen Protects Against Increased Blood Pressure in Postpubertal Female Growth Restricted Offspring Hypertension, October 1, 2007; 50(4): 679 - 685. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. A. Brookhart, A. R. Patrick, C. Dormuth, J. Avorn, W. Shrank, S. M. Cadarette, and D. H. Solomon Adherence to Lipid-lowering Therapy and the Use of Preventive Health Services: An Investigation of the Healthy User Effect Am. J. Epidemiol., August 1, 2007; 166(3): 348 - 354. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. M. Everett, T. Kurth, J. E. Buring, and P. M. Ridker The Relative Strength of C-Reactive Protein and Lipid Levels as Determinants of Ischemic Stroke Compared With Coronary Heart Disease in Women J. Am. Coll. Cardiol., December 5, 2006; 48(11): 2235 - 2242. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. de Vries, C. de Vries, C. Cooper, B. Leufkens, and T.-P. van Staa Reanalysis of two studies with contrasting results on the association between statin use and fracture risk: the General Practice Research Database. Int. J. Epidemiol., October 1, 2006; 35(5): 1301 - 1308. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. D. McCully, Y. Toyoda, H. Wakiyama, A. J. Rousou, R. A. Parker, and S. Levitsky Age- and gender-related differences in ischemia/reperfusion injury and cardioprotection: effects of diazoxide. Ann. Thorac. Surg., July 1, 2006; 82(1): 117 - 123. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Kim, S. Evans, L. Smeeth, and S. Pocock Hormone replacement therapy and acute myocardial infarction: a large observational study exploring the influence of age Int. J. Epidemiol., June 1, 2006; 35(3): 731 - 738. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. Hayden, P. Cote, and C. Bombardier Evaluation of the quality of prognosis studies in systematic reviews. Ann Intern Med, March 21, 2006; 144(6): 427 - 437. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 The Florida Behavioral Health Research Consortium, M. A. Burg, K. Fraser, S. Gui, K. Grant, S. G. Kosch, B. Nierenberg, O. Oyama, H. Pomm, K. Sibille, et al. Treatment of Menopausal Symptoms in Family Medicine Settings following the Women's Health Initiative Findings J Am Board Fam Med, March 1, 2006; 19(2): 122 - 131. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. N. Lemaitre, N. S. Weiss, N. L. Smith, B. M. Psaty, T. Lumley, E. B. Larson, and S. R. Heckbert Esterified estrogen and conjugated equine estrogen and the risk of incident myocardial infarction and stroke. Arch Intern Med, February 27, 2006; 166(4): 399 - 404. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Wang, S. Oparil, Y.-F. Chen, M. A. McCrory, G. A. Skibinski, W. Feng, and A. J. Szalai Estrogen Treatment Abrogates Neointima Formation in Human C-Reactive Protein Transgenic Mice Arterioscler. Thromb. Vasc. Biol., October 1, 2005; 25(10): 2094 - 2099. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. B. Petitti and D. A. Freedman Invited Commentary: How Far Can Epidemiologists Get with Statistical Adjustment? Am. J. Epidemiol., September 1, 2005; 162(5): 415 - 418. [Full Text] [PDF]
|
|
|
|
|
|
R. L. Prentice, R. Langer, M. L. Stefanick, B. V. Howard, M. Pettinger, G. Anderson, D. Barad, J. D. Curb, J. Kotchen, L. Kuller, et al. Combined Postmenopausal Hormone Therapy and Cardiovascular Disease: Toward Resolving the Discrepancy between Observational Studies and the Women's Health Initiative Clinical Trial Am. J. Epidemiol., September 1, 2005; 162(5): 404 - 414. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
U.S. Preventive Services Task Force* Hormone Therapy for the Prevention of Chronic Conditions in Postmenopausal Women: Recommendations from the U.S. Preventive Services Task Force Ann Intern Med, May 17, 2005; 142(10): 855 - 860. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Mamdani, K. Sykora, P. Li, S.-L. T Normand, D. L Streiner, P. C Austin, P. A Rochon, and G. M Anderson Reader's guide to critical appraisal of cohort studies: 2. Assessing potential for confounding BMJ, April 23, 2005; 330(7497): 960 - 962. [Full Text] [PDF]
|
|
|
|
 |
|
 J.-P. Delille, P. J. Slanetz, E. D. Yeh, D. B. Kopans, E. F. Halpern, and L. Garrido Hormone Replacement Therapy in Postmenopausal Women: Breast Tissue Perfusion Determined with MR Imaging--Initial Observations Radiology, April 1, 2005; 235(1): 36 - 41. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. K. Dubey, B. Imthurn, L. C. Zacharia, and E. K. Jackson Hormone Replacement Therapy and Cardiovascular Disease: What Went Wrong and Where Do We Go From Here? Hypertension, December 1, 2004; 44(6): 789 - 795. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. B. Peterson, S. B. Thacker, P. S. Corso, P. A. Marchbanks, and J. P. Koplan Hormone Therapy: Making Decisions in the Face of Uncertainty Arch Intern Med, November 22, 2004; 164(21): 2308 - 2312. [Full Text] [PDF]
|
|
|
|
|
|
E. von Elm and M. Egger The scandal of poor epidemiological research BMJ, October 16, 2004; 329(7471): 868 - 869. [Full Text] [PDF]
|
|
|
|
 |
|
 Coronary Heart Disease Obstet. Gynecol., October 1, 2004; 104(4_suppl): 41S - 48S. [Full Text] [PDF]
|
|
|
|
|
|
D. Petitti Commentary: Hormone replacement therapy and coronary heart disease: four lessons Int. J. Epidemiol., June 1, 2004; 33(3): 461 - 463. [Full Text] [PDF]
|
|
|
|
|
|
M. Stampfer Commentary: Hormones and heart disease: do trials and observational studies address different questions? Int. J. Epidemiol., June 1, 2004; 33(3): 454 - 455. [Full Text] [PDF]
|
|
|
|
|
|
D. A Lawlor, G. Davey Smith, and S. Ebrahim Commentary: The hormone replacement-coronary heart disease conundrum: is this the death of observational epidemiology? Int. J. Epidemiol., June 1, 2004; 33(3): 464 - 467. [Full Text] [PDF]
|
|
|
|
|
|
E. Barrett-Connor Commentary: Observation versus intervention--what's different? Int. J. Epidemiol., June 1, 2004; 33(3): 457 - 459. [Full Text] [PDF]
|
|
|
|
 |
|
 H. D. Nelson Commonly Used Types of Postmenopausal Estrogen for Treatment of Hot Flashes: Scientific Review JAMA, April 7, 2004; 291(13): 1610 - 1620. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. D. Nelson Postmenopausal Estrogen for Treatment of Hot Flashes: Clinical Applications JAMA, April 7, 2004; 291(13): 1621 - 1625. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. B. Ritterband and I. A. Jaffe Postmenopausal Hormone Replacement Therapy and Cardiovascular Disease Ann Intern Med, March 2, 2004; 140(5): 402 - 402. [Full Text] [PDF]
|
|
|
|
|
|
N. F. Col and S. G. Pauker The Discrepancy between Observational Studies and Randomized Trials of Menopausal Hormone Therapy: Did Expectations Shape Experience? Ann Intern Med, December 2, 2003; 139(11): 923 - 929. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. A. Ray Evaluating Medication Effects Outside of Clinical Trials: New-User Designs Am. J. Epidemiol., November 1, 2003; 158(9): 915 - 920. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Wang-Cheng and J. A. Rosenfeld Hormone replacement therapy BMJ, October 6, 2003; 327(7418): E139 - 140. [Full Text] [PDF]
|
|
|
|
 |
|
 E. A. Booth, M. Marchesi, E. J. Kilbourne, and B. R. Lucchesi 17{beta}-Estradiol as a Receptor-Mediated Cardioprotective Agent J. Pharmacol. Exp. Ther., October 1, 2003; 307(1): 395 - 401. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Barrett-Connor Diabetes and Heart Disease Diabetes Care, October 1, 2003; 26(10): 2947 - 2958. [Full Text] [PDF]
|
|
|
|
|
|
A. P. Miller, Y.-F. Chen, D. Xing, W. Feng, and S. Oparil Hormone Replacement Therapy and Inflammation: Interactions in Cardiovascular Disease Hypertension, October 1, 2003; 42(4): 657 - 663. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Barrett-Connor An Epidemiologist Looks at Hormones and Heart Disease in Women J. Clin. Endocrinol. Metab., September 1, 2003; 88(9): 4031 - 4042. [Full Text] [PDF]
|
|
|
|
|
|
J. V.L. Sheffield and E. B. Larson Update in General Internal Medicine Ann Intern Med, August 19, 2003; 139(4): 285 - 293. [Full Text] [PDF]
|
|
|
|
|
|
S. J. Meyerson Postmenopausal Hormone Replacement Therapy Ann Intern Med, April 15, 2003; 138(8): 687 - 687. [Full Text] [PDF]
|
|
|
|
|
|
F. Grodstein, J. E. Manson, and M. J. Stampfer Postmenopausal Hormone Replacement Therapy Ann Intern Med, April 15, 2003; 138(8): 688 - 688. [Full Text] [PDF]
|
|
|
|
|
|
A. B. Chausmer Postmenopausal Hormone Replacement Therapy Ann Intern Med, April 15, 2003; 138(8): 687 - 688. [Full Text] [PDF]
|
|
|
|
 |
|
 R. Paoletti and N. K. Wenger Review of the International Position Paper on Women's Health and Menopause: A Comprehensive Approach Circulation, March 11, 2003; 107(9): 1336 - 1339. [Full Text] [PDF]
|
|
|
|
|
|
P. P. Zandi and J. C. S. Breitner Estrogen Replacement and Risk of Alzheimer Disease--Reply JAMA, March 5, 2003; 289(9): 1101 - 1102. [Full Text] [PDF]
|
|
|
|
 |
|
 G. Colditz Review: observational studies adjusting for socioeconomic status and lifestyle show no association between HRT and CAD Evid. Based Med., March 1, 2003; 8(2): 46 - 46. [Full Text] [PDF]
|
|
|
|
|
|
L. A. Fortepiani, H. Zhang, L. Racusen, L. J. Roberts II, and J. F. Reckelhoff Characterization of an Animal Model of Postmenopausal Hypertension in Spontaneously Hypertensive Rats Hypertension, March 1, 2003; 41(3): 640 - 645. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Grodstein, T. B. Clarkson, and J. E. Manson Understanding the Divergent Data on Postmenopausal Hormone Therapy N. Engl. J. Med., February 13, 2003; 348(7): 645 - 650. [Full Text] [PDF]
|
|
|
|
|
|
D. A. Grimes and R. A. Lobo Perspectives on the Women's Health Initiative Trial of Hormone Replacement Therapy Obstet. Gynecol., December 1, 2002; 100(6): 1344 - 1353. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
U.S. Preventive Services Task Force* Postmenopausal Hormone Replacement Therapy for Primary Prevention of Chronic Conditions: Recommendations and Rationale Ann Intern Med, November 19, 2002; 137(10): 834 - 839. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Laine Postmenopausal Hormone Replacement Therapy: How Could We Have Been So Wrong? Ann Intern Med, August 20, 2002; 137(4): 290 - 290. [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Article
